Kanamycin is a type of antibiotic medicine. It's made by a specific type of bacteria. Doctors use it to treat certain types of infections, usually in the urinary tract or other parts of the body. It works by stopping the growth of harmful bacteria.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Kanamycin, once sold in the US under the brand name Kantrex, is an injectable antibiotic from the aminoglycoside family. Its labeled use is short-term treatment of serious bacterial infections caused by germs that test as susceptible to it, mainly gram-negative bacteria such as E. coli, Klebsiella, Proteus, Enterobacter, Serratia and Acinetobacter. When the cause of a serious infection is not yet known, it could be started alongside a penicillin-type or cephalosporin-type antibiotic while lab results are pending. It was not a first choice for staph infections, but could be used in specific situations, such as in people allergic to other antibiotics. In the US, every kanamycin product approved for people, including Kantrex injection and capsules, is now listed by the Food and Drug Administration as discontinued. Outside the US, kanamycin was long used as an injectable medicine for drug-resistant tuberculosis (TB). The World Health Organization stopped recommending it for drug-resistant TB in 2019 because regimens that included it were linked to more treatment failure, relapse, deaths and side effects than newer, all-oral regimens. The US label also states that it is not meant for long-term treatment such as TB, because the risk of toxicity grows with longer use.
Kanamycin kills bacteria by stopping them from making the proteins they need to survive. It acts on bacteria only, so it has no effect on viral infections such as colds. The body does not break kanamycin down. The kidneys filter almost all of it out unchanged, which concentrates the drug in the kidneys and urine. This explains its two main risks: the kidneys themselves are exposed to high levels, and when the kidneys work less well, the drug builds up in the blood, where higher levels raise the chance of damage to the inner ear.
Kanamycin is given by health professionals, usually in a hospital, either as an injection deep into a large muscle such as the buttock or as a slow infusion into a vein over 30 to 60 minutes. The daily amount is split into two or three doses. The dose is calculated from body weight (estimated lean weight in people with obesity) and adjusted to kidney function, which is measured before and during treatment. When the kidneys clear the drug more slowly, the doses are spaced further apart. The care team may also measure blood levels of the drug at their highest point after a dose and just before the next one, to keep levels effective without reaching a toxic range. A typical course lasts 7 to 10 days, and the label sets a ceiling of 1.5 grams a day by all routes combined.
The main concern with kanamycin is damage to hearing and balance. Hearing loss usually affects both ears, starts with high-pitched sounds and is often permanent. Early damage may cause no symptoms and show up only on a hearing test, and hearing can keep getting worse for a while after the drug is stopped. Damage to the balance system can cause dizziness, a spinning sensation (vertigo), nausea and unsteadiness. Ringing or roaring in the ears, any change in hearing, dizziness or vertigo should be reported to the nurse or care team right away, because these signs call for a dose change or stopping the drug. Kanamycin can also injure the kidneys, which is why kidney blood and urine tests are repeated during treatment. These kidney changes usually reverse once the drug is stopped. Less often, it affects nerves, causing numbness, tingling or muscle twitching, which should also be reported promptly; seizures have also been reported. Some pain or irritation can follow an injection into a muscle. Rash, fever, headache, nausea, vomiting and diarrhea occur occasionally.
The risk of hearing and kidney damage rises sharply with existing kidney problems, high doses or long courses, older age and dehydration. Drinking enough fluid or receiving it by vein during treatment helps protect the kidneys. A past allergic or toxic reaction to any aminoglycoside (such as gentamicin, tobramycin, amikacin or streptomycin) may rule kanamycin out. Kanamycin should not be combined with other drugs that can harm the kidneys or nerves, because the damage can add up. These include other aminoglycosides, vancomycin and polymyxin B or colistin (antibiotics often used for resistant infections), amphotericin B (an antifungal) and cisplatin (a chemotherapy drug). It also should not be given with strong diuretics (water pills) such as furosemide, some of which can harm hearing on their own. Aminoglycosides can block the signals between nerves and muscles, which in rare cases causes muscle paralysis and stopped breathing. The risk is highest around anesthesia or with muscle-relaxing drugs, so the surgical and anesthesia team must know about kanamycin treatment. The same effect can worsen weakness in people with myasthenia gravis or Parkinson's disease. Aminoglycosides cross the placenta and can harm a developing baby. Permanent deafness has been reported in babies whose mothers received the related drug streptomycin during pregnancy, so anyone who is or may be pregnant should discuss the risk. The injection contains sodium bisulfite, a sulfite preservative that can trigger allergic-type reactions or asthma attacks in sensitive people, more often in people with asthma. Finally, roughly 1 in 330 people carry an inherited mitochondrial gene variant that makes aminoglycoside hearing loss likely, sometimes after a single dose. A family history of deafness after these antibiotics is worth mentioning before treatment.
Treatment is closely monitored. Expect repeated blood tests of kidney function and drug levels, urine tests, and, when practical, hearing tests (audiograms) before and during treatment, especially for people at higher risk or on longer courses. Hearing tests may be repeated after treatment if any change in hearing or balance appeared. An uncomplicated infection caused by susceptible bacteria is expected to start improving within 24 to 48 hours. If there is no clear response within 3 to 5 days, the care team rechecks whether the bacteria are truly susceptible or whether an abscess or other source of infection needs draining. Because hearing damage can progress after the last dose, new hearing or balance problems in the weeks after treatment are worth reporting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Kanamycin, what you've noticed, or ask the community a question.